keyword
https://read.qxmd.com/read/38551742/lnccpset1-acts-as-a-scaffold-for-mll2-compass-to-regulate-bmp4-and-promote-the-formation-of-chicken-primordial-germ-cells
#1
JOURNAL ARTICLE
Ying Ding, Chen Zhang, Qisheng Zuo, Kai Jin, Bichun Li
Primordial germ cells (PGCs) are the ancestors of female and male germ cells. Recent studies have shown that long non-coding RNA (lncRNA) and histone methylation are key epigenetic factors affecting PGC formation; however, their joint regulatory mechanisms have rarely been studied. Here, we explored the mechanism by which lncCPSET1 and H3K4me2 synergistically regulate the formation of chicken PGCs for the first time. Combined with chromatin immunoprecipitation (CHIP) sequencing and RNA-seq of PGCs transfected with the lncCPSET1 overexpression vector, GO annotation and KEGG enrichment analysis revealed that Wnt and TGF-β signaling pathways were significantly enriched, and Fzd2, Id1, Id4, and Bmp4 were identified as candidate genes...
March 29, 2024: Molecular Genetics and Genomics: MGG
https://read.qxmd.com/read/38513661/h3k4me1-facilitates-promoter-enhancer-interactions-and-gene-activation-during-embryonic-stem-cell-differentiation
#2
JOURNAL ARTICLE
Naoki Kubo, Poshen B Chen, Rong Hu, Zhen Ye, Hiroyuki Sasaki, Bing Ren
Histone H3 lysine 4 mono-methylation (H3K4me1) marks poised or active enhancers. KMT2C (MLL3) and KMT2D (MLL4) catalyze H3K4me1, but their histone methyltransferase activities are largely dispensable for transcription during early embryogenesis in mammals. To better understand the role of H3K4me1 in enhancer function, we analyze dynamic enhancer-promoter (E-P) interactions and gene expression during neural differentiation of the mouse embryonic stem cells. We found that KMT2C/D catalytic activities were only required for H3K4me1 and E-P contacts at a subset of candidate enhancers, induced upon neural differentiation...
March 15, 2024: Molecular Cell
https://read.qxmd.com/read/38460250/comprehensive-genomic-profiling-to-identify-actionable-alterations-for-breast-cancer-brain-metastases-in-the-chinese-population
#3
JOURNAL ARTICLE
Q Lu, N Wang, K Jiang, H Zhou, P Zhang, J Zhang, S Wang, P Sun, F Xu
BACKGROUND: Breast cancer brain metastasis (BCBM) is a crucial issue in the treatment of breast cancer and is associated with poor prognosis. Therefore, novel therapeutic targets are urgently needed in clinical practice. In this study, we aimed to identify potential actionable targets in brain metastases (BMs) utilising the FoundationOne® CDx (F1CDx). PATIENTS AND METHODS: Formalin-fixed paraffin-embedded archived specimens including 16 primary breast tumours (PTs), 49 BCBMs and 7 extracranial metastases (ECMs) from 54 patients who underwent surgery for BCBM were tested using F1CDx...
March 8, 2024: ESMO Open
https://read.qxmd.com/read/38254937/kmt2d-deficiency-causes-sensorineural-hearing-loss-in-mice-and-humans
#4
JOURNAL ARTICLE
Allison J Kalinousky, Teresa R Luperchio, Katrina M Schrode, Jacqueline R Harris, Li Zhang, Valerie B DeLeon, Jill A Fahrner, Amanda M Lauer, Hans T Bjornsson
Individuals with Kabuki syndrome type 1 (KS1) often have hearing loss recognized in middle childhood. Current clinical dogma suggests that this phenotype is caused by frequent infections due to the immune deficiency in KS1 and/or secondary to structural abnormalities of the ear. To clarify some aspects of hearing loss, we collected information on hearing status from 21 individuals with KS1 and found that individuals have both sensorineural and conductive hearing loss, with the average age of presentation being 7 years...
December 28, 2023: Genes
https://read.qxmd.com/read/37974198/epigenetic-focused-crispr-cas9-screen-identifies-absent-small-or-homeotic-2-like-protein-ash2l-as-a-regulator-of-glioblastoma-cell-survival
#5
JOURNAL ARTICLE
Ezgi Ozyerli-Goknar, Ezgi Yagmur Kala, Ali Cenk Aksu, Ipek Bulut, Ahmet Cingöz, Sheikh Nizamuddin, Martin Biniossek, Fidan Seker-Polat, Tunc Morova, Can Aztekin, Sonia H Y Kung, Hamzah Syed, Nurcan Tuncbag, Mehmet Gönen, Martin Philpott, Adam P Cribbs, Ceyda Acilan, Nathan A Lack, Tamer T Onder, H T Marc Timmers, Tugba Bagci-Onder
BACKGROUND: Glioblastoma is the most common and aggressive primary brain tumor with extremely poor prognosis, highlighting an urgent need for developing novel treatment options. Identifying epigenetic vulnerabilities of cancer cells can provide excellent therapeutic intervention points for various types of cancers. METHOD: In this study, we investigated epigenetic regulators of glioblastoma cell survival through CRISPR/Cas9 based genetic ablation screens using a customized sgRNA library EpiDoKOL, which targets critical functional domains of chromatin modifiers...
November 16, 2023: Cell Communication and Signaling: CCS
https://read.qxmd.com/read/37921399/attention-challenges-in-kabuki-syndrome
#6
JOURNAL ARTICLE
A J Kalinousky, T Rapp, J R Harris
BACKGROUND: Understanding the specific neurobehavioural profile of rare genetic diseases enables clinicians to provide the best possible care for patients and families, including prognostic and treatment advisement. Previous studies suggested that a subset of individuals with Kabuki syndrome (KS), a genetic disorder causing intellectual disability and other neurodevelopmental phenotypes, have attentional deficits. However, these studies looked at relatively small numbers of molecularly confirmed cases and often used retrospective clinical data instead of standardised assessments...
November 3, 2023: Journal of Intellectual Disability Research: JIDR
https://read.qxmd.com/read/37822508/kmt2d-suppresses-sonic-hedgehog-driven-medulloblastoma-progression-and-metastasis
#7
JOURNAL ARTICLE
Reeti Mayur Sanghrajka, Richard Koche, Hector Medrano, Salsabiel El Nagar, Daniel N Stephen, Zhimin Lao, N Sumru Bayin, Kai Ge, Alexandra L Joyner
The major cause of treatment failure and mortality among medulloblastoma patients is metastasis intracranially or along the spinal cord. The molecular mechanisms driving tumor metastasis in Sonic hedgehog-driven medulloblastoma (SHH-MB) patients, however, remain largely unknown. In this study we define a tumor suppressive role of KMT2D ( MLL2 ), a gene frequently mutated in the most metastatic β-subtype. Strikingly, genetic mouse models of SHH-MB demonstrate that heterozygous loss of Kmt2d in conjunction with activation of the SHH pathway causes highly penetrant disease with decreased survival, increased hindbrain invasion and spinal cord metastasis...
October 20, 2023: IScience
https://read.qxmd.com/read/37749819/genetic-insights-into-thymic-carcinomas-and-thymic-neuroendocrine-neoplasms-denote-prognosis-signatures-and-pathways
#8
JOURNAL ARTICLE
Shuyuan Wang, Zhitao Gu, Lei Zhu, Yuchen Han, Hong Yu, Wentao Fang, Baohui Han
BACKGROUND: Thymic carcinomas (TCs) and thymic neuroendocrine neoplasms (TNENs) are two aggressive subtypes of thymic malignancy. Traditional therapy for advanced TCs and TNENs has limited outcome. New genomic profiling of TCs and TNENs might provide insights that contribute to the development of new treatment approaches. METHODS: We used gene panel sequencing technologies to investigate the genetic aberrations of 32 TC patients and 15 TNEN patients who underwent surgery at Shanghai Chest Hospital between 2015 and 2017...
September 25, 2023: Chinese Medical Journal
https://read.qxmd.com/read/37720048/the-pml1-wdr5-axis-regulates-h3k4me3-marks-and-promotes-stemness-of-estrogen-receptor-positive-breast-cancer
#9
Hung-Ying Kao, Chun-Peng Pai, Han Wang, Neel Agarwal, Joshua Adams, Zhenghao Liu, Darcie Seachrist, Ruth Keri, William Schiemann
The alternative splicing of PML precursor mRNA gives rise to various PML isoforms, yet their expression profile in breast cancer cells remains uncharted. We discovered that PML1 is the most abundant isoform in all breast cancer subtypes, and its expression is associated with unfavorable prognosis in estrogen receptor-positive (ER+) breast cancers. PML depletion reduces cell proliferation, invasion, and stemness, while heterologous PML1 expression augments these processes and fuels tumor growth and resistance to fulvestrant, an FDA-approved drug for ER + breast cancer, in a mouse model...
September 8, 2023: Research Square
https://read.qxmd.com/read/37711591/clinical-and-mutational-profile-of-at-rich-interaction-domain-1a-mutated-cancers
#10
JOURNAL ARTICLE
Rosa Falcone, Marco Filetti, Pasquale Lombardi, Valeria Altamura, Francesco Paroni Sterbini, Giovanni Scambia, Gennaro Daniele
AIM: AT-rich interaction domain 1A ( ARID1A ) encodes a key component of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex that participates in gene expression. ARID1A alterations are quite common among cancer patients, although their role remains debated. The aim of this article was to study ARID1A-mutated cancer patients. METHODS: Molecular and clinical data of cancer patients evaluated at Phase 1 Unit of Fondazione Policlinico Universitario A...
2023: Exploration of targeted anti-tumor therapy
https://read.qxmd.com/read/37142078/mechanisms-of-hedgehog-calcium-and-retinoic-acid-signalling-pathway-inhibitors-plausible-modes-of-action-along-the-mll-ezh2-p53-axis-in-cellular-growth-control
#11
JOURNAL ARTICLE
Soumen Manna, R Kirtana, Ankan Roy, Tirthankar Baral, Samir Kumar Patra
Understanding the molecular mechanism(s) of small compounds in cellular growth control are essential for using those against the disease(s). Oral cancers exhibit a very high mortality rate due to higher metastatic potential. Aberrant EGFR, RAR, HH signalling, enhanced [Ca2+ ] and oxidative stress are some of the important characteristics of oral cancer. So, we target these for our study. Herein, we tested the effect of fendiline hydrochloride (FH) as an LTCC Ca2+ -channel inhibitor, erismodegib (a SMO inhibitor of HH-signalling) and all-trans retinoic acid (RA) inducer of RAR signalling that causes cellular differentiation...
May 2, 2023: Archives of Biochemistry and Biophysics
https://read.qxmd.com/read/37140208/kmt2d-links-tgf-%C3%AE-signaling-to-noncanonical-activin-pathway-and-regulates-pancreatic-cancer-cell-plasticity
#12
JOURNAL ARTICLE
Shuang Lu, Hong Sun Kim, Yubo Cao, Karan Bedi, Lili Zhao, Ishwarya Venkata Narayanan, Brian Magnuson, Yumei Gu, Jing Yang, Zhujun Yi, Sepideh Babaniamansour, Sargis Shameon, Chang Xu, Michelle T Paulsen, Ping Qiu, Sivakumar Jeyarajan, Mats Ljungman, Dafydd Thomas, Yali Dou, Howard Crawford, Marina Pasca di Magliano, Kai Ge, Bo Yang, Jiaqi Shi
Although KMT2D, also known as MLL2, is known to play an essential role in development, differentiation, and tumor suppression, its role in pancreatic cancer development is not well understood. Here, we discovered a novel signaling axis mediated by KMT2D, which links TGF-β to the activin A pathway. We found that TGF-β upregulates a microRNA, miR-147b, which in turn leads to post-transcriptional silencing of KMT2D. Loss of KMT2D induces the expression and secretion of activin A, which activates a noncanonical p38 MAPK-mediated pathway to modulate cancer cell plasticity, promote a mesenchymal phenotype, and enhance tumor invasion and metastasis in mice...
May 4, 2023: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/36917966/waldenstr%C3%A3-m-macroglobulinemia-and-non-igm-type-lymphoplasmacytic-lymphoma-are-genetically-similar
#13
JOURNAL ARTICLE
Maaya Awata-Shiraiwa, Akihiko Yokohama, Yukihiro Kanai, Nanami Gotoh, Tetsuhiro Kasamatsu, Hiroshi Handa, Takayuki Saitoh, Hirokazu Murakami, Junko Hirato, Hayato Ikota, Norifumi Tsukamoto
INTRODUCTION: Waldenström macroglobulinemia (WM) represents a subset of lymphoplasmacytic lymphoma (LPL) with the immunoglobulin (Ig)M paraprotein. MYD88 L265P and CXCR4 mutations are common mutations in WM patients, and mutations in ARID1A and KMT2D (MLL2) have also been reported. However, little information has been accumulated on genetic changes in LPL with other paraproteins like IgG. METHODS: We therefore aimed to evaluate genetic differences between WM and LPL with non-IgM paraprotein (non-IgM-type LPL) using targeted next-generation sequencing (NGS) in 20 Japanese patients (10 with WM, 10 with non-IgM-type LPL)...
2023: Acta Haematologica
https://read.qxmd.com/read/36644235/cell-free-dna-in-cerebrospinal-fluid-complements-the-monitoring-value-of-interleukin-10-in-newly-diagnosed-primary-central-nervous-system-lymphoma
#14
JOURNAL ARTICLE
Wei Wang, DongMei Zou, Zhe Zhuang, Xiao Zhang, Li Zhang, JingJing Yin, CongWei Jia, Li Yuan, Hao Cai, Yan Zhang, Xuan Wang, MeiFen Zhang, DaoBin Zhou, Wei Zhang
OBJECTIVES: Primary central nervous system lymphoma (PCNSL) usually has a poor prognosis. Cerebrospinal fluid (CSF) interleukin (IL)-10 has shown diagnostic, prognostic, and monitoring value in our previous studies. Cell-free circulating tumor DNA can be detected in the CSF of refractory/relapse cases and has also shown monitoring value. However, information about its monitoring value in newly diagnosed PCNSL patients and comparisons of CSF IL-10 and CSF cell-free DNA (cfDNA) are scarce...
2023: Journal of Oncology
https://read.qxmd.com/read/36596519/bet-inhibitors-induce-p53-independent-growth-arrest-in-hct116-cells-via-epigenetic-control-of-the-e2f1-c-myc-axis
#15
JOURNAL ARTICLE
DoYeong Jeon, Nackhyoung Kim, Soo-Jong Um
Although bromodomain and extraterminal (BET) inhibitors (BETis) have anti-tumor potential, the underlying molecular mechanism is poorly understood. We found that BETis effectively repressed cell growth via G1/S arrest and migration of HCT116 cells in a p53-independent manner. BETis increased the expression of p21WAF1 and repressed the expression of E2F target genes. Consistent with this, retinoblastoma protein (Rb) phosphorylation was downregulated by BETis, supporting E2F inactivation. To investigate the epigenetic mechanism, chromatin immunoprecipitation (ChIP) assays were employed using the E2F1 target gene c-MYC...
2023: Biological & Pharmaceutical Bulletin
https://read.qxmd.com/read/36371186/swi-snf-complex-gene-variations-are-associated-with-a-higher-tumor-mutational-burden-and-a-better-response-to-immune-checkpoint-inhibitor-treatment-a-pan-cancer-analysis-of-next-generation-sequencing-data-corresponding-to-4591-cases
#16
JOURNAL ARTICLE
Yue Li, Xinhua Yang, Weijie Zhu, Yuxia Xu, Jiangjun Ma, Caiyun He, Fang Wang
BACKGROUND: Genes related to the SWItch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex are frequently mutated across cancers. SWI/SNF-mutant tumors are vulnerable to synthetic lethal inhibitors. However, the landscape of SWI/SNF mutations and their associations with tumor mutational burden (TMB), microsatellite instability (MSI) status, and response to immune checkpoint inhibitors (ICIs) have not been elucidated in large real-world Chinese patient cohorts. METHODS: The mutational rates and variation types of six SWI/SNF complex genes (ARID1A, ARID1B, ARID2, SMARCA4, SMARCB1, and PBRM1) were analyzed retrospectively by integrating next-generation sequencing data of 4591 cases covering 18 cancer types...
November 12, 2022: Cancer Cell International
https://read.qxmd.com/read/36313704/corrigendum-lncrna-foxp4-as1-promotes-the-progression-of-esophageal-squamous-cell-carcinoma-by-interacting-with-mll2-h3k4me3-to-upregulate-foxp4
#17
Yunfeng Niu, Gaoyan Wang, Yan Li, Wei Guo, Yanli Guo, Zhiming Dong
[This corrects the article DOI: 10.3389/fonc.2021.773864.].
2022: Frontiers in Oncology
https://read.qxmd.com/read/36283211/prognostic-impact-of-tumour-mutational-burden-in-resected-stage-i-and-ii-lung-adenocarcinomas-from-a-european-thoracic-oncology-platform-lungscape-cohort
#18
JOURNAL ARTICLE
Lukas Bubendorf, Martin Zoche, Urania Dafni, Jan Hendrik Rüschoff, Spasenija Savic Prince, Nesa Marti, Androniki Stavrou, Roswitha Kammler, Stephen P Finn, Holger Moch, Solange Peters, Rolf A Stahel
BACKGROUND: The primary objective of this study is to evaluate tumor mutational burden (TMB), its associations with selected clinicopathological and molecular characteristics as well as its clinical significance, in a retrospective cohort of surgically resected stage I-II lung adenocarcinomas, subset of the ETOP Lungscape cohort. METHODS: TMB was evaluated on tumor DNA extracted from resected primary lung adenocarcinomas, based on FoundationOne®CDx (F1CDx) genomic profiling, centrally performed at the University Hospital Zurich...
October 13, 2022: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/36276984/neurobehavioral-phenotype-of-kabuki-syndrome-anxiety-is-a-common-feature
#19
JOURNAL ARTICLE
Allison J Kalinousky, Tyler Rapp, Hadia Hijazi, Jennifer Johnson, Hans Tomas Bjornsson, Jacqueline R Harris
Kabuki syndrome (KS) is a Mendelian Disorder of the Epigenetic Machinery (MDEM) caused by loss of function variants in either of two genes involved in the regulation of histone methylation, KMT2D (34-76%) or KDM6A (9-13%). Previously, representative neurobehavioral deficits of KS were recapitulated in a mouse model, emphasizing the role of KMT2D in brain development, specifically in ongoing hippocampal neurogenesis in the granule cell layer of the dentate gyrus. Interestingly, anxiety, a phenotype that has a known association with decreased hippocampal neurogenesis, has been anecdotally reported in individuals with KS...
2022: Frontiers in Genetics
https://read.qxmd.com/read/36239901/the-role-of-epigenetics-in-t-cell-lymphoma
#20
REVIEW
Makoto Yamagishi
Malignant lymphomas are a group of diseases with epigenomic abnormalities fundamental to pathogenesis and pathophysiology. They are characterized by a high frequency of abnormalities related to DNA methylation regulators (DNMT3A, TET2, IDH2, etc.) and histone modifiers (EZH2, HDAC, KMT2D/MLL2, CREBBP, EP300, etc.). These epigenomic abnormalities directly amplify malignant clones. They also originate from a hematopoietic stem cell-derived cell lineage triggered by epigenomic changes. These characteristics are linked to their high affinity for epigenomic therapies...
October 14, 2022: International Journal of Hematology
keyword
keyword
21051
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.